Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Purpose: To evaluate the holistic cost of longer acting anti-VEGF therapy for macular degeneration when considering the associated costs of travel to the retina clinic. Design: Theoretical evaluation of cost using publicly available pricing data and reimbursements at the Veterans Affairs (VA) Medical Center. Patients and Methods: Setting: VA Medical Center. Study population: Patients with age related macular degeneration. Main outcome measures: Three-year cost of therapy when considering medication as well as travel costs and time spent in transit. Results: Based on cost data derived purely from wholesale acquisition cost and projected injection frequency over the first three years of treatment, faricimab is less expensive than ranibizumab and aflibercept by $37,709 and $6359, respectively. Aflibercept is less expensive ranibizumab by $31,350 over the first 3 years of treatment. When considering even small distances traveled by patients, these cost differences grow, amplified at even larger distances: at 25 miles, ranibizumab becomes $38,814 and $32,133 more expensive than faricimab and aflibercept, respectively. Aflibercept becomes $6681 more expensive than faricimab. At 100 miles, ranibizumab becomes $41,502 and $34,038 more expensive than faricimab and aflibercept, respectively. Aflibercept becomes $7464 more expensive than faricimab. Conclusion: Longer acting anti-VEGF therapies may differ not only in their wholesale acquisition cost, but also in the frequency of per label injections and associated clinic visits. Taking into account distance and time cost of travel may contribute to a more holistic view of cost differences among these therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the high price of anti-VEGFs contributes to increasing costs, their long-term associated care – requiring careful follow-up and monitoring from skilled practitioners - is also a financial strain on patients and health systems that is not fully captured by current costing studies [12, 13, 67].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Despite the effectiveness of anti-VEGF injections in stabilizing and, even in some cases, reversing these conditions demonstrated in clinical trials [10], their high price compounded with their long-term associated care represent a strain on health systems and patients [11–13].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Theory of the Allocation of Time
Becker, G. S. (1965) · The Economic Journal · doi:10.2307/2228949 · Cited by 10,354
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822
Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00010-1 · Cited by 785 · cited 1×
“79 injections in the first year.(10) The wholesale acquisition prices (ie the public pricing before any negotiated discounts not necessarily the actual proprietary costs paid by the payer) included $2190 for faricimab 5 mg, $1950 for ranibizumab 0.”
Maguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Ho, A. C., Busbee, B. G., Regillo, C. D., Wieland, M. R., Van Everen, S. A., Li, Z., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.009 · Cited by 590
Research works printed but not linked: 6
- Rosenfeld, 2006, N Engl J Med, 355, 1419, 10.1056/NEJMOA054481/SUPPL_FILE/NEJM_ROSENFELD_SA1.PDF · doi:10.1056/nejmoa054481/suppl_file/nejm_rosenfeld_sa1.pdf
- Khanani, 2021, Invest Ophthalmol Vis Sci, 62, 428
- Li, 2020, Cochrane Database Syst Rev, 2020, 10.1002/14651858.CD012208.PUB2/MEDIA/CDSR/CD012208/IMAGE_N/NCD012208-CMP-004.03.SVG · doi:10.1002/14651858.cd012208.pub2/media/cdsr/cd012208/image_n/ncd012208-cmp-004.03.svg
- 2016, Cost-Effectiveness in Health and Medicine
- Ray, 2015, Am J Manag Care, 21, 567
- Gelfand, 2021, Front Psychol, 12, 3785, 10.3389/FPSYG.2021.727871/BIBTEX · doi:10.3389/fpsyg.2021.727871/bibtex
Cited by
Leung, E. H., Oh, D. J., Alderson, S. E., Bracy, J., McLeod, M., Perez, L. I., Bottini, A. R., Yee, D. C., & Mukkamala, K. (2023) · Clinical ophthalmology · doi:10.2147/opth.s409822 · Cited by 99
“could improve its cost-effectiveness compared to the other anti-VEGFs due to the decreased time and travel burdens for patients and their caretakers with less injections.(16) The limitations of the study include the retrospective nature and relatively short follow-up.”
BackgroundSelf-citationPanos, G. D., Lakshmanan, A., Dadoukis, P., Ripa, M., Motta, L., & Amoaku, W. M. K. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s427416 · Cited by 98
“Cost-Effectiveness A theoretical cost-saving analysis from San Francisco, CA, USA aimed to assess the cost of use of faricimab, ranibizumab, and aflibercept over the first 3 years of initial injection administration.(41) The study took into account the wholesale acquisition prices for the medications, the frequency of…”
BackgroundReitan, G., Haugen, I. B. K., Andersen, K., Bragadóttir, R., & Bindesbøll, C. (2023) · Clinical ophthalmology · doi:10.2147/opth.s409103 · Cited by 72
“In this report, valuation and inclusion of some of the central elements from this survey, for example the time used by patients and caregivers and travel costs, clearly demonstrated how the differences in costs between the treatments increased substantially as compared to only considering the medicine costs.(36) In th…”
BackgroundJanmohamed, I. K., Mushtaq, A., Kabbani, J., Harrow, S., Nadarajasundaram, A., Ata, A., Monye, H. I., Jarrar, Z. A., Hannan, S., & Membrey, L. (2025) · Eye · doi:10.1038/s41433-025-03616-5 · Cited by 21
Annuryanti, F., Adhami, M., Abdi, U., Domínguez‐Robles, J., Larrañeta, E., Vora, L. K., & Singh, T. R. R. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125099 · Cited by 18
Downey, L., Sivaprasad, S., Chhabra, R., Bailey, C., Chakrabarti, S., Elsherbiny, S., Patel, J. I., Silvestri, G., Watson, S., Williams, G. S., et al. (2024) · Eye · doi:10.1038/s41433-024-03223-w · Cited by 18
“…led outpatient visits, nurse or technician-led monitoring, consultant-led reviews, post injection management and overall episode costs); capacity improvements over time, supported by modelling assumptions of injection frequencies through years 3–5; and impact on patients and their carers [64, 65].”
BackgroundDolar-Szczasny, J., Drab, A., & Ręjdak, R. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1442758 · Cited by 18
Friedman, S. M., Xu, Y., Sherman, S. A., Kuznik, A., Mojebi, A., Keeping, S. T., Chan, K., Leng, T., & Patel, N. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01247-3 · Cited by 20
“A less intensive, flexible dosing regimen may have additional benefits for patients, including less time lost attending appointments [52], less disruption to normal life [24], and less anxiety [25–27].”
Kuznik, A., Coughlan, A., Pinsent, A., Toro‐Díaz, H., Sherman, S. A., & Patel, N. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01236-6 · Cited by 8
“…analysis are consistent with those of a prior analysis, which showed that intravitreal anti‑VEGF therapies that are associated with fewer versus greater number of injections provide greater indirect cost sav‑ ings, as the number of injection visits, and con‑ sequently travel time, decrease [25].”
Endophthalmitis following same-day bilateral anti-VEGF injections: a systematic review
Bjerager, J., Hajari, J. N., Klefter, O. N., Subhi, Y., & Schneider, M. (2024) · International Ophthalmology · doi:10.1007/s10792-024-02983-4 · Cited by 5
“Most patients need regular injections, typically every 4 to 16 months, depending on the type of anti-VEGF and the patient’s response to the treatment [4].”
Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration
Hao, Q., & Bailey, S. M. (2023) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2023.771 · Cited by 4
Shafiee, A., Juran, T., Zabaneh, I. D., Patel, D., & Allison, K. M. (2025) · Journal of Clinical & Translational Ophthalmology · doi:10.3390/jcto3030016 · Cited by 4
“Given that the different medications have proven to be equivalent in functionality and morphology, ocular improvements provided the largest difference in their respective half-lives and injection schedules based on medication pharmacokinetics and pharmacodynamics [32,33].”
InfluentialMeer, E. A., Targ, S., Zhang, N., Hoggatt, K. J., Mehta, K. M., & Brodie, F. L. (2023) · Retina · doi:10.1097/iae.0000000000003947 · Cited by 3
“16,22,23 Therefore, in this study, we sought to explore whether the addition of a travel support might mediate the inverse association between distance and frequency of injection.”
BackgroundSelf-citationGene Therapy for Wet Age-Related Macular Degeneration
Barthelemy, N., Sridhar, J. S., & Sengillo, J. D. (2025) · Bioengineering · doi:10.3390/bioengineering12101072 · Cited by 6
“Holistic cost-saving analysis studies across longer-acting anti-VEGF agents found that they differ in acquisition cost and in the frequency of required injections [9].”
Access and affordability of intravitreal injections in albania: a cross-sectional survey
Krasniqi, M., & Dalani, S. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/miwcsthtc6 · Cited by 2
Soylu, C., Corradetti, G., Alhelaly, M., Khan, H., Aziz, A. A., Khan, H., Ali, H., Sulahria, H., Khanani, A. M., & Sadda, S. R. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.08.018 · Cited by 2
Zhang, X., Cui, B., Liu, Y., Ji, X., Tian, X., Hou, S., Yang, L., & Yang, J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1745453 · Cited by 1
Kim, J. H., Kim, C. G., & Kim, C. G. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06144-8 · Cited by 1
“Thus, long-lasting treatment can help patients reduce these burdens and subsequently contribute to better treatment outcomes [11, 12].”
BackgroundWillmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
“Despite the effectiveness of anti-VEGF injections in stabilizing and, even in some cases, reversing these conditions demonstrated in clinical trials [10], their high price compounded with their long-term associated care represent a strain on health systems and patients [11–13].”
Adoption patterns of anti-vascular endothelial growth factor therapies in retinal disease
Kozlov, M., Sadeghi, E., & Chhablani, J. K. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07492-x
Mallepally, A., Lam, M., Mittal, E., Mahmoudzadeh, R., Salabati, M., & Randolph, J. (2026) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264261484033
Metadata
- Authors
- Meer, E. A., Oh, D. H., & Brodie, F. L.
- Affiliations
- University of California, San Francisco (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Brodie, Frank L
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2022-12
- Volume
- Volume 16
- Pages
- 4273-4279
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC9792116
- OpenAlex
- W4312070261
- Cited by
- 21
- References
- 32
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 4 · 2023: 6
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- age-related macular degeneration, anti-VEGF therapy, faricimab, ranibizumab, aflibercept, drug cost comparison, travel cost, time costs, clinic visits, Veterans Affairs hospitals, wholesale acquisition cost, injection frequency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.